Pictet Asset Management Holding SA lessened its stake in shares of Humana Inc. (NYSE:HUM – Free Report) by 1.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 65,811 shares of the insurance provider’s stock after selling 1,201 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Humana were worth $25,112,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Pinnacle Wealth Planning Services Inc. grew its stake in Humana by 21.8% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 151 shares of the insurance provider’s stock valued at $58,000 after buying an additional 27 shares during the last quarter. Wilkerson Advisory Group LLC boosted its holdings in shares of Humana by 24.6% during the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock worth $66,000 after acquiring an additional 33 shares during the period. Cidel Asset Management Inc. boosted its holdings in shares of Humana by 1.1% during the second quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider’s stock worth $1,542,000 after acquiring an additional 41 shares during the period. Greenleaf Trust grew its position in shares of Humana by 1.7% in the third quarter. Greenleaf Trust now owns 2,524 shares of the insurance provider’s stock valued at $963,000 after purchasing an additional 41 shares during the last quarter. Finally, Bogart Wealth LLC grew its position in shares of Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock valued at $29,000 after purchasing an additional 48 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently weighed in on HUM. Barclays lifted their price target on Humana from $582.00 to $587.00 and gave the stock an “overweight” rating in a report on Monday. Zacks Research lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Deutsche Bank initiated coverage on Humana in a report on Thursday, July 30th. They set a “hold” rating for the company. Raymond James Financial reissued an “outperform” rating on shares of Humana in a research report on Friday, November 6th. Finally, Guggenheim upped their price target on shares of Humana from $471.00 to $521.00 and gave the company a “buy” rating in a research note on Monday. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $472.17.
Key Stories Impacting Humana
Here are a few of the latest stories about HUM:
- Positive Sentiment: Humana’s stronger earnings outlook has bolstered optimism: the company raised its 2026 adjusted EPS floor to $9.50 from $9.00 after reporting favorable insurance-benefit metrics. A Zacks upgrade to Rank #1 (Strong Buy) adds to the positive earnings sentiment. Article: Humana Upgraded to Strong Buy
- Positive Sentiment: Several analysts have lifted price targets following the earnings update. JPMorgan raised its target to $484, while TD Cowen increased its target to $430, reflecting improved expectations even as the firms retained neutral or hold ratings. Article: JPMorgan raises Humana price target
- Negative Sentiment: TD Cowen’s $430 target remains below the cited share price, and its Hold rating suggests the firm sees limited near-term upside at current levels. Article: TD Cowen raises Humana price target
Humana Trading Up 1.9%
Shares of HUM stock opened at $446.33 on Thursday. The company has a current ratio of 1.65, a quick ratio of 1.74 and a debt-to-equity ratio of 0.61. The stock has a market cap of $53.60 billion, a P/E ratio of 43.42, a price-to-earnings-growth ratio of 2.30 and a beta of 0.65. The stock has a 50 day simple moving average of $406.79 and a 200 day simple moving average of $314.80. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $456.50.
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 8.50% and a net margin of 0.81%. The business had revenue of $41.16 billion for the quarter, compared to the consensus estimate of $40.87 billion. During the same quarter in the prior year, the business posted $3.24 earnings per share. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. On average, research analysts predict that Humana Inc. will post 9.56 earnings per share for the current fiscal year.
Humana Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be issued a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s dividend payout ratio is 34.44%.
Humana Profile
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Recommended Stories
- Five stocks we like better than Humana
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
